Functional hepatic flow in patients with liver cirrhosis.
OBJECTIVE
To evaluate hepatic reserve function by investigating the change of functional hepatic flow and total hepatic flow in cirrhotic patients with portal hypertension.


METHODS
HPLC method was employed for the determination of concentration of D-sorbitol in human plasma and urine. The functional hepatic flow (FHF) and total hepatic flow (THF) were determined by means of modified hepatic clearance of D-sorbitol combined with duplex doppler color sonography in 20 patients with cirrhosis and 10 healthy volunteers.


RESULTS
FHF, evaluated by means of the D-sorbitol clearance, was significantly reduced in patients with cirrhosis in comparison to controls (764.74+/-167.91 vs 1195.04+/-242.97 mL/min, P<0.01). While THF was significantly increased in patients with cirrhosis in comparison to controls (1605.23+/-279.99 vs 1256.12+/-198.34 mL/min, P<0.01). Portal blood flow and hepatic artery flow all were increased in cirrhosis compared to controls (P<0.05 and P<0.01). D-sorbitol total clearance was significantly reduced in cirrhosis compared to control (P<0.01), while D-sorbitol renal clearance was significantly increased in cirrhosis (P<0.05). In controls FHF was similar to THF (1195.05+/-242.97 vs 1256.12+/-198.34 mL/min, P=0.636), while FHF was significantly reduced compared with THF in cirrhosis (764.74+/-167.91 vs 1605.23+/-279.99 mL/min, P<0.01).


CONCLUSIONS
Our method that combined modified hepatic clearance of D-sorbitol with duplex doppler color sonography is effective in the measurement of FHF and THF. FHF can be used to estimate hepatic reserve function.
Pan
Zheng
Z
Research Institute of General Surgery, Nanjing General Hospital of Nanjing Command, No.305, Eastern Road of Zhongshan, Nanjing 210002, Jiangsu Province, China. pz2233@sina.com
Wu
Xing-Jiang
XJ
Li
Jie-Shou
JS
Liu
Fang-Nan
FN
Li
Wei-Su
WS
Han
Jian-Ming
JM
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006499:Hepatic Artery / Q000503:physiopathology; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications*; D007202:Indicators and Reagents / Q000493:pharmacokinetics; D007668:Kidney / Q000378:metabolism; D008102:Liver Circulation; D008103:Liver Cirrhosis / Q000209:etiology* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011168:Portal System / Q000503:physiopathology; D013012:Sorbitol / Q000493:pharmacokinetics
D007202:Indicators and Reagents; D013012:Sorbitol